Terminated PHASE3 INTERVENTIONAL 2-arm NCT00990327

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI (ASPECT)

The ASPECT Trial: A Phase III, Randomized, Double-Blind Crossover Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

Sponsor: Forest Laboratories

Conditions Coronary Artery Disease

Interventions Adenosine SPECT-MPI Apadenoson SPECT-MPI

Updated 10 times since 2017 Last updated: Apr 27, 2012 Started: Nov 30, 2009 Primary completion: Apr 30, 2012 Completion: Apr 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Forest Laboratories

See all terminations from Forest Laboratories

Other Coronary Artery Disease trials with similar outcome

Browse all Coronary Artery Disease trials

This PHASE3 trial investigates Coronary Artery Disease and is currently terminated or withdrawn. Forest Laboratories leads this study, which shows 10 recorded versions since 2009 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Jun 2025 — Sep 2025 [monthly]

Terminated PHASE3
Oct 2024 — Jun 2025 [monthly]

Terminated PHASE3
Sep 2024 — Oct 2024 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3

▶ Show 5 earlier versions

Apr 2022 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Apr 2022 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Forest Laboratories
PPD Development, LP

Data source: Forest Laboratories

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Albany, United States , Alexandria, United States , Amarillo, United States , Auburn, United States , Augusta, United States , Baltimore, United States , Belo Horizonte - MG, Brazil , Bend, United States , Birmingham, United States and 94 more locations